Aurobindo receives nod for generic Millipred

The Food and Drug Administration has given Aurobindo the green light for prednisolone tablets, 5 mg, which are the generic of Watson Laboratories’ Millipred.

Prednisolone tablets are indicated in the following conditions: endocrine disorders; rheumatic disorders; collagen diseases; dermatologic diseases; allergic states; ophthalmic diseases; respiratory diseases; hematologic disorders; neoplastic diseases; edematous states; gastrointestinal diseases; nervous system; tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; and trichinosis with neurologic or myocardial involvement.

[Read more: Aurobindo receives FDA approval for 3 generics]

Prednisolone tablets have a market value of roughly $3.2 million for the 12 months ending March 2023, per IQVIA.

[Read more: Aurobindo obtains FDA OK for 2 generics]